Compare GCT & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | ALVO |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | GCT | ALVO |
|---|---|---|
| Price | $36.09 | $3.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $33.00 | $8.00 |
| AVG Volume (30 Days) | 621.1K | ★ 638.7K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.70 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,161,042,000.00 | N/A |
| Revenue This Year | $14.43 | $13.28 |
| Revenue Next Year | $6.78 | $18.63 |
| P/E Ratio | $34.40 | ★ $18.20 |
| Revenue Growth | ★ 64.96 | N/A |
| 52 Week Low | $20.71 | $2.94 |
| 52 Week High | $51.82 | $9.94 |
| Indicator | GCT | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 35.84 |
| Support Level | $35.33 | $2.99 |
| Resistance Level | $36.31 | $3.94 |
| Average True Range (ATR) | 1.40 | 0.17 |
| MACD | 0.21 | -0.03 |
| Stochastic Oscillator | 54.42 | 0.98 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.